Tests fat-derived cells to heal hand ulcers in scleroderma

Trial details

Who runs it

University Hospital, Toulouse

Trial code

NCT04356755

Record updated

31 December 2025

Original description

Ischemic digital ulcers (DUs) are a frequent complication in systemic sclerosis with a major impact on hand function and quality of life. Digital injection of cultured adipose-derived stromal cell (AdMSC) constitutes a promising approach to treat scleroderma-induced refractory ischemic DUs where no alternative therapy is validated. The aim of this phase 2 study is to compare efficacy and safety of digital injection of AdMSC versus placebo for healing refractory active ischemic digital ulcers in patients with systemic sclerosis.Read full original descriptionShow less

Subcutaneous Injections of Cultured Adipose-derived Stroma/ Stem Cells to Heal Refractory Ischemic Digital Ulcers in Patients With Scleroderma

Ischemic digital ulcers (DUs) are a frequent complication in systemic sclerosis with a major impact on hand function and quality of life. Digital injection of cultured adipose-derived stromal cell (AdMSC) constitutes a promising approach to treat scleroderma-induced refractory ischemic DUs where no alternative therapy is validated. The aim of this phase 2 study is to compare efficacy and safety of digital injection of AdMSC versus placebo for healing refractory active ischemic digital ulcers in patients with systemic sclerosis.

Inclusion: Male or female patient ≥18 years of age,; Patient with systemic sclerosis according to the 2013 ACR/EULAR classification criteria9,; SSc patient with at least one refractory active ischemic digital ulcer at "inclusion visit" (see below the eligibility conditions of a DU),; Age > 50 years and not treated with any kind of hormone replacement therapy for at least 2 years prior to screening, with amenorrhea for at least 24 consecutive months prior to screening. An assessment of serum follicle stimulating hormone showing a level of > 40 TU/L at screening may be used to exclude childbearing potential, based on the discretion of the investigator,; Patient must have provided written informed consent prior to enrolment,; Patient must be able to understand their requirements of participating in the protocol,; Patient affiliated to a social security system; Relative to each DU :; The DU at " inclusion visit " must show all the following characteristics:; Located beyond the proximal interphalangeal joint, on finger surface (included periungual ulcers),; Of ischemic origin according to the physician,; Not over subcutaneous calcifications or bone relief,; Active DU,; Refractory after 10±2 weeks of standard of care according to EULAR recommendations26 (that is either still active (chronic) or new occurrence despite standard of care).

Exclusion: Current smoker or tobacco consumption stopped for less than 3 months prior to inclusion, - Patient participating in a clinical trial or having participated in a clinical trial within the previous 3 months,; Patients on statins, who have received treatment for less than 3 months prior to Screening or whose treatment has not been stable during this period,; Treatment with disease modifying agents such as methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, Interferons and cyclophosphamide, those drugs should be stop at least 1 month prior study entry; Treatment with oral corticosteroids (> 10 mg/day of prednisone or equivalent),; Systemic antibiotics (oral and TV) to treat infected DU(s) within 4 weeks prior to "inclusion visit",; Local injection of botulinum toxin in an affected finger within 4 weeks prior to "inclusion visit",; Surgical sympathectomy of the upper limbs or surgical wound debridement within 1 month prior to "inclusion visit",; Patient who underwent autologous hematopoietic stem cell transplantation (HSCT) within less than 1 year,; History of cancer in the last five years, except for successfully excised basal cell/squamous cell carcinoma, or successfully excised early melanoma of the skin. Subjects, who had successfully tumor resection or radiation or chemotherapy more than 5 years from inclusion and no recurrence, may be enrolled in the study, - Subjects who have active proliferative retinopathy,; Positive HIV-1 or 2, HTLV-1 or 2, HBV or HCV,; Patients with a history of stroke, myocardial infarction or severe arrhythmia in the last 6 months; Patient who had severe cardiac failure in the last 6 months,; Relative to each DU:; Digital ulcer due to conditions other than scleroderma,; Non ischemic digital ulcer,; Ulcers with osteomyelitis, or clinically uncontrolled infection,; Infected digital ulcer requiring systemic antibiotherapy,; Digital ulcer requiring urgent surgery; Patients on vasodilators, such as endothelin receptor antagonists (ERAs), PDE5 inhibitors (e.g. sildenafil, tadalafil), calcium channel blockers, ACE-inhibitors, nitroglycerin, alpha adrenergic blockers, or angiotensin II receptor antagonists, N-acetylcysteine, antiplatelet aggregation therapy and low molecular weight heparin who have received treatment if present for less than 3 months prior to "inclusion visit" or whose treatment has not been stable for at least 1 month prior to "inclusion visit",; Use of topical growth factors, hyperbaric oxygen,; Liposuction technically impossible,; Patients with an indication for intensification by autologous HSCT (according to EBMT guidelines and national RCP MATHEC),; Females who are pregnant or breastfeeding or plan to do so during the course of this study,; Patient under judicial protection, - Refusal of the patient to participate in the study.

ClinicalTrials.gov NCT04356755